Facioscapulohumeral Disease as a myodevelopmental disease: Applying Ockham's razor to its various features.

 Facioscapulohumeral muscular dystrophy (FSHD) is an exclusively human neuromuscular disease. In the last decades the cause of FSHD was identified: the loss of epigenetic repression of the D4Z4 repeat on chromosome 4q35 resulting in inappropriate transcription of DUX4. This is a consequence of a reduction of the array below 11 units (FSHD1) or of a mutation in methylating enzymes (FSHD2). Both require the presence of a 4qA allele and a specific centromeric SSLP haplotype. Muscles become involved in a rostro-caudally order with an extremely variable progression rate. Mild disease and non-penetrance in families with affected individuals is common. Furthermore, 2% of the Caucasian population carries the pathological haplotype without clinical features of FSHD.In order to explain the various features of FSHD we applied Ockham's Razor to all possible scenarios and removed unnecessary complexities. We postulate that early in embryogenesis a few cells escape epigenetic silencing of the D4Z4 repeat. Their number is assumed to be roughly inversely related to the residual D4Z4 repeat size. By asymmetric cell division, they produce a rostro-caudal and medio-lateral decreasing gradient of weakly D4Z4-repressed mesenchymal stem cells. The gradient tapers towards an end as each cell-division allows renewed epigenetic silencing. Over time, this spatial gradient translates into a temporal gradient based on a decreasing number of weakly silenced stem cells. These cells contribute to a mildly abnormal myofibrillar structure of the fetal muscles. They also form a downward tapering gradient of epigenetically weakly repressed satellite cells. When activated by mechanical trauma, these satellite cells de-differentiate and express DUX4. When fused to myofibrils they contribute to muscle cell death in various ways. Over time and dependent on how far the gradient reaches the FSHD phenotype becomes progressively manifest. We thus hypothesize FSHD to be a myodevelopmental disease with a lifelong attempt to restore DUX4 repression.

[1]  P. Zammit,et al.  Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies , 2022, European journal of translational myology.

[2]  Dave W. Oyler,et al.  Persistent Fibroadipogenic Progenitor Expansion Following Transient DUX4 Expression Provokes a Profibrotic State in a Mouse Model for FSHD , 2022, International journal of molecular sciences.

[3]  S. Jagannathan The evolution of DUX4 gene regulation and its implication for facioscapulohumeral muscular dystrophy. , 2022, Biochimica et biophysica acta. Molecular basis of disease.

[4]  K. Mamchaoui,et al.  Interplay between mitochondrial reactive oxygen species, oxidative stress and hypoxic adaptation in facioscapulohumeral muscular dystrophy: Metabolic stress as potential therapeutic target , 2022, Redox biology.

[5]  F. Magdinier,et al.  Facioscapulohumeral dystrophy weakened sarcomeric contractility is mimicked in induced pluripotent stem cells‐derived innervated muscle fibres , 2021, Journal of cachexia, sarcopenia and muscle.

[6]  M. Pannese,et al.  DUX4 Role in Normal Physiology and in FSHD Muscular Dystrophy , 2021, Cells.

[7]  F. Rossi,et al.  Emerging skeletal muscle stromal cell diversity: Functional divergence in fibro/adipogenic progenitor and mural cell populations. , 2021, Experimental cell research.

[8]  N. van Alfen,et al.  Natural History of Facioscapulohumeral Dystrophy in Children , 2021, Neurology.

[9]  P. Muñoz-Cánoves,et al.  Muscle repair after physiological damage relies on nuclear migration for cellular reconstruction , 2021, Science.

[10]  N. Voermans,et al.  1st FSHD European Trial Network workshop:Working towards trial readiness across Europe , 2021, Neuromuscular Disorders.

[11]  B. Cairns,et al.  p53 convergently activates Dux/DUX4 in embryonic stem cells and in facioscapulohumeral muscular dystrophy cell models , 2021, Nature Genetics.

[12]  C. Banerji,et al.  Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7 , 2021, EMBO molecular medicine.

[13]  B. Chadwick,et al.  CRISPR mediated targeting of DUX4 distal regulatory element represses DUX4 target genes dysregulated in Facioscapulohumeral muscular dystrophy , 2021, Scientific Reports.

[14]  A. Paulussen,et al.  Facioscapulohumeral muscular dystrophy—Reproductive counseling, pregnancy, and delivery in a complex multigenetic disease , 2021, Clinical genetics.

[15]  V. Somers,et al.  Cardiac Involvement in Facioscapulohumeral Muscular Dystrophy (FSHD) , 2021, Frontiers in Neurology.

[16]  L. Joosten,et al.  Profiling Serum Antibodies Against Muscle Antigens in Facioscapulohumeral Muscular Dystrophy Finds No Disease-Specific Autoantibodies , 2021, Journal of neuromuscular diseases.

[17]  H. Deigner,et al.  Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update , 2021, Orphanet Journal of Rare Diseases.

[18]  H. Clevers,et al.  Tissue regeneration: Reserve or reverse? , 2021, Science.

[19]  F. Dilworth,et al.  Epigenetic regulation of satellite cell fate during skeletal muscle regeneration , 2021, Skeletal muscle.

[20]  B. Brand-Saberi,et al.  The CXCR4/SDF-1 Axis in the Development of Facial Expression and Non-somitic Neck Muscles , 2020, Frontiers in Cell and Developmental Biology.

[21]  C. Horlings,et al.  Characterizing the face in facioscapulohumeral muscular dystrophy , 2020, Journal of Neurology.

[22]  Yi-Wen Chen,et al.  DUX4 transcript knockdown with antisense 2'-O-methoxyethyl gapmers for the treatment of facioscapulohumeral muscular dystrophy. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  A. Heerschap,et al.  Reduced specific force in patients with mild and severe facioscapulohumeral muscular dystrophy , 2020, Muscle & nerve.

[24]  Ayellet V. Segrè,et al.  The impact of sex on gene expression across human tissues , 2020, Science.

[25]  H. Masumoto,et al.  Damaged Myofiber-Derived Metabolic Enzymes Act as Activators of Muscle Satellite Cells , 2020, Stem cell reports.

[26]  J. Jaiswal,et al.  Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy , 2020, International journal of molecular sciences.

[27]  M. Kyba,et al.  Transcriptional and cytopathological hallmarks of FSHD in chronic DUX4-expressing mice. , 2020, The Journal of clinical investigation.

[28]  S. Kuang,et al.  Temporal Dynamics and Heterogeneity of Cell Populations during Skeletal Muscle Regeneration , 2020, iScience.

[29]  K. Lim,et al.  DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy , 2020, International journal of molecular sciences.

[30]  A. Heerschap,et al.  Preserved single muscle fiber specific force in facioscapulohumeral muscular dystrophy , 2020, Neurology.

[31]  Peter L Jones,et al.  The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy. , 2019, Annual review of genomics and human genetics.

[32]  C. Banerji,et al.  PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level , 2019, Human molecular genetics.

[33]  J. Statland,et al.  Effects of weakness of orofacial muscles on swallowing and communication in FSHD , 2019, Neurology.

[34]  G. Andersen,et al.  Relationship between muscle inflammation and fat replacement assessed by MRI in facioscapulohumeral muscular dystrophy , 2019, Journal of Neurology.

[35]  J. Statland,et al.  Early onset as a marker for disease severity in facioscapulohumeral muscular dystrophy , 2019, Neurology.

[36]  Simone Severini,et al.  Dynamic transcriptomic analysis reveals suppression of PGC1/ERR drives perturbed myogenesis in facioscapulohumeral muscular dystrophy , 2018 .

[37]  L. Kunkel,et al.  Transgenic zebrafish model of DUX4 misexpression reveals a developmental role in FSHD pathogenesis , 2018, Human molecular genetics.

[38]  C. Horlings,et al.  Phenotype‐genotype relations in facioscapulohumeral muscular dystrophy type 1 , 2018, Clinical genetics.

[39]  S. Tapscott,et al.  Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle. , 2018, Human molecular genetics.

[40]  C. Nicoletti,et al.  Denervation-activated STAT3–IL-6 signalling in fibro-adipogenic progenitors promotes myofibres atrophy and fibrosis , 2018, Nature Cell Biology.

[41]  C. Horlings,et al.  A family-based study into penetrance in facioscapulohumeral muscular dystrophy type 1 , 2018, Neurology.

[42]  L. Bains,et al.  Oxidative capacity varies along the length of healthy human tibialis anterior , 2018, The Journal of physiology.

[43]  H. Lochmüller,et al.  Chronic pain has a strong impact on quality of life in facioscapulohumeral muscular dystrophy , 2017, Muscle & nerve.

[44]  E. Ricci,et al.  Muscle Microdialysis to Investigate Inflammatory Biomarkers in Facioscapulohumeral Muscular Dystrophy , 2018, Molecular Neurobiology.

[45]  B. Engelen,et al.  Early onset facioscapulohumeral dystrophy – a systematic review using individual patient data , 2017, Neuromuscular Disorders.

[46]  Olivier Pourquié,et al.  Making muscle: skeletal myogenesis in vivo and in vitro , 2017, Development.

[47]  M. Buckingham Gene regulatory networks and cell lineages that underlie the formation of skeletal muscle , 2017, Proceedings of the National Academy of Sciences.

[48]  B. Engelen,et al.  225th ENMC international workshop: A global FSHD registry framework, 18–20 November 2016, Heemskerk, The Netherlands , 2017, Neuromuscular Disorders.

[49]  A. Geurts,et al.  Upper limb function and activity in people with facioscapulohumeral muscular dystrophy: a web-based survey , 2017, Disability and rehabilitation.

[50]  N. Saunders,et al.  DUX4 Is Derepressed in Late-Differentiating Keratinocytes in Conjunction with Loss of H3K9me3 Epigenetic Repression. , 2016, The Journal of investigative dermatology.

[51]  C. Horlings,et al.  What's in a name? The clinical features of facioscapulohumeral muscular dystrophy , 2016, Practical Neurology.

[52]  A. Falini,et al.  Muscle MRI findings in facioscapulohumeral muscular dystrophy , 2016, European Radiology.

[53]  S. Tapscott,et al.  Muscle pathology grade for facioscapulohumeral muscular dystrophy biopsies , 2015, Muscle & nerve.

[54]  S. Tapscott,et al.  Immunohistochemical Characterization of FacioscapulohumeralMuscular Dystrophy Muscle Biopsies , 2015, Journal of neuromuscular diseases.

[55]  N. Voermans,et al.  Facioscapulohumeral muscular dystrophy as a genetic cause of pectus excavatum. , 2015, European journal of medical genetics.

[56]  O. King,et al.  Individual epigenetic status of the pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular dystrophy , 2015, Clinical Epigenetics.

[57]  S. Severini,et al.  β-catenin is central to DUX4-driven network rewiring in facioscapulohumeral muscular dystrophy , 2015, Journal of The Royal Society Interface.

[58]  A. Geurts,et al.  Both aerobic exercise and cognitive-behavioral therapy reduce chronic fatigue in FSHD , 2014, Neurology.

[59]  O. King,et al.  Identifying diagnostic DNA methylation profiles for facioscapulohumeral muscular dystrophy in blood and saliva using bisulfite sequencing , 2014, Clinical Epigenetics.

[60]  A. Verbeek,et al.  Population-based incidence and prevalence of facioscapulohumeral dystrophy , 2014, Neurology.

[61]  E. Mercuri,et al.  Upper Girdle Imaging in Facioscapulohumeral Muscular Dystrophy , 2014, PloS one.

[62]  F. Magdinier,et al.  P.16.3 DUX4 and DUX4 downstream target genes are expressed in fetal FSHD muscles , 2013, Neuromuscular Disorders.

[63]  F. Sera,et al.  Large scale genotype–phenotype analyses indicate that novel prognostic tools are required for families with facioscapulohumeral muscular dystrophy , 2013, Brain : a journal of neurology.

[64]  T. Partridge The mdx mouse model as a surrogate for Duchenne muscular dystrophy , 2013, The FEBS journal.

[65]  L. Santoro,et al.  Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy. , 2012, American journal of human genetics.

[66]  A. Verrotti,et al.  Epilepsy, speech delay, and mental retardation in facioscapulohumeral muscular dystrophy. , 2011, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[67]  Raffaele Iorio,et al.  CD8+ T Cells in Facioscapulohumeral Muscular Dystrophy Patients with Inflammatory Features at Muscle MRI , 2011, Journal of Clinical Immunology.

[68]  Daniel G. Miller,et al.  A Unifying Genetic Model for Facioscapulohumeral Muscular Dystrophy , 2010, Science.

[69]  G. Carnac,et al.  Myoblasts from affected and non-affected FSHD muscles exhibit morphological differentiation defects , 2008, Journal of cellular and molecular medicine.

[70]  L. Kunkel,et al.  Transcriptional regulation differs in affected facioscapulohumeral muscular dystrophy patients compared to asymptomatic related carriers , 2009, Proceedings of the National Academy of Sciences.

[71]  Mario Quarantelli,et al.  Modifications of brain tissue volumes in facioscapulohumeral dystrophy , 2006, NeuroImage.

[72]  K. Flanigan,et al.  Sarcolemmal reorganization in facioscapulohumeral muscular dystrophy , 2006, Annals of neurology.

[73]  R. Frants,et al.  Contractions of D4Z4 on 4qB subtelomeres do not cause facioscapulohumeral muscular dystrophy. , 2004, American journal of human genetics.

[74]  M. Dorobek,et al.  A severe case of facioscapulohumeral muscular dystrophy (FSHD) with some uncommon clinical features and a short 4q35 fragment. , 2004, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[75]  L. Sandkuijl,et al.  Mechanism and timing of mitotic rearrangements in the subtelomeric D4Z4 repeat involved in facioscapulohumeral muscular dystrophy. , 2004, American journal of human genetics.

[76]  E. Bakker,et al.  Somatic mosaicism in FSHD often goes undetected , 2004, Annals of neurology.

[77]  I. Nonaka,et al.  Sarcolemmopathy: Muscular Dystrophies with Cell Membrane Defects , 2001, Brain pathology.

[78]  L. Sandkuijl,et al.  De novo facioscapulohumeral muscular dystrophy: frequent somatic mosaicism, sex-dependent phenotype, and the role of mitotic transchromosomal repeat interaction between chromosomes 4 and 10. , 2000, American journal of human genetics.

[79]  R. Griggs,et al.  Monozygotic twins with facioscapulohumeral dystrophy (FSHD): Implications for genotype/phenotype correlation , 1995, Muscle & nerve. Supplement.

[80]  I. Nonaka,et al.  Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): Immunocytochemical and genetic analyses , 1995, Muscle & nerve. Supplement.

[81]  C. Wijmenga,et al.  Facioscapulohumeral muscular dystrophy in the dutch population , 1995, Muscle & nerve. Supplement.

[82]  C. Wijmenga,et al.  The FSHD‐linked locus D4F104S1 (p13E‐11) ON 4q35 has a homologue on 10qter , 1995, Muscle & nerve. Supplement.

[83]  E. Bakker,et al.  Early onset facioscapulohumeral muscular dystrophy , 1995, Muscle & nerve. Supplement.

[84]  J. Bodensteiner,et al.  Intracellular calcium accumulation in Duchenne dystrophy and other myopathies , 1978, Neurology.